Cyclosporine-induced depressive psychosis in a liver transplant patient: A case report;Depresivna psihoza inducirana ciklosporinom u bolesnice s transplantiranom jetrom (prikaz bolesnika)

Lijecnicki Vjesnik

Volumn 129, Issue 3-4, 2007, Pages 74-76

  Telarović, Siniša ^a   Telarović, Srdana ^b   Mihanović, Mate ^a  

^a brankarestek petrovic pbsvihr   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Adverse effects, therapeutic use, administration and dosage; Depressive disorders; Adverse effects, therapeutic use, administration and dosage; Immunosuppressive agents; Chemically induced; Psychoses, substance induced; Cyclosporine

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DEPRESSION; FEMALE; HUMAN; LIVER TRANSPLANTATION; MIDDLE AGED;

CYCLOSPORINE; DEPRESSIVE DISORDER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIDDLE AGED;

EID: 34249774005     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fleming PS, Flood TR. Steroid-induced psychosis complicating orthognatic surgery: a case report. Br Dent J 2005;199:647-8.
2. Hall RCW, Beresford TP. Psychiatric manifestation of physical illnes. U: Michels R, Cavenar JO, Brodie HKH, ur. Psychiatry. Philadelphia: J B. Lippencott Co;1989, str. 9.
3. Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf 2000;22(2):111-22.
4. Wada K, Yamada N, Sato T i sur. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics 2001;42 (6):461-6.
5. Duval F, Mokrani MC, Crocq MA i sur. Dopaminergic function and the cortisol response to dexamethasone in psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2000;24 (2):207-25.
6. Trzepacz PT, Levenson JL, Triangali RA. Psychopharmacology and neuropsychiatric syndromes in organ transplantation. Gen Hosp Psychiatry 1991;13:233-45.
7. de Groen P, Craven J. Organic brain syndromes in transplant patients. U: Craven J, Rodin GR, ur. Psychiatric aspects of organ transplantation. Oxford: Oxford University Press; 1992, str. 67-88.
8. Tarter RE, Van Thiel DH, Hegedus AM. Neuropsychiatric status after liver transplantation. J Lab Clin Med 1984;103:776-82.
9. Beresford TP. Neuropsychiatric complications of liver and other solid organ transplantation. Liver Transpl 2001;11:536-45.
10. Shibolet O, Galun E, Bishara A, Eid A, Birmanns B, Ilan Y. Major neurological complications following liver transplantation. Transplant Proc 2001;33:2959.
11. Craven JL. Cyclosporine-associated organic mental disorders in liver transplantant recipients. Psychosomatics 1991;32:94-102.
12. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995;45:1962-4.
13. Rifai K, Kirschner GI, Bahr MJ i sur. A new side effect of immunosuppression: High incidence of hearing impairment after liver transplantation. Liver Transpl 2006;2.
14. Lopez OL, Martinez AJ, Torre-Cisneros J. Neuropathologic findings in liver transplantation: A comparative study of cyclosporine and FK 506. Transplant Proc 1991;23:3181-3182.
15. Yamauchi A, Shuto H, Dohgu S i sur. Cyclosporin A aggravates electro-shock-induced convulsions in mice with a transient middle cerebral artery occlusion. Cell Mol Neurobiol 2005;25:923-8.
16. Beveridge T. Pharmacokinetics and metabolism of cyclosporin A. Proceedings of an International conference on cyclosporin A. Cambridge, 1981.
17. Ishizawa T, Sugawara Y, Ikeda M, Hasegawa K, Makuuchi M. Optimal initial dose of orally administered cyelosporine following intravenous cyclosporine therapy. Transplant Proc 2005;37:4370-2.
18. Calne RY, Rolles K, White DJG. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979;2:1033-6.
19. Fukudo M, Yano J, Masuda S i sur. Cyclosporine exposure and calcineurin phosphatase activity in living -donor liver transplant patients: twice daily vs. once daily dosing. Liver Transpl 2006;12:292-300.
20. Berden JHM, Hoitsma AJ, Merx JL, Keyser A. Severe central-nervous-system toxicity associated with cyclosporin. Lancet 1985;1:219-20.
21. Federico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V. Pharmacokinetic interaction between levofloxacin and cyelosporine or tacrolimus in kidney transplant recipients: cyclosporine, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet 2006;45:169-75.
22. Gurecki J, Warty V, Sanghvi A. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients. Transplant Proc 1985;17:1997-2002.
23. Piet C, de Groen P, Allen JA, Jorge R, Glenn SF, Ruud AF. Central nervous system toxicity after liver transplantation - The role of cyclosporine and cholesterol. N Engl J Med 1987;14:861-6.
24. Zawaideh MA, Ghishan FK, Molmenti EP. Regulation of cholesterol homeostasis in solid organ transplantation. Transplantation 2006;81:316-7.
25. Nemunaitis J, Deeg HJ, Yee GC. High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridemia. Lancet 1986;2:744-5.
26. Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 1984;2:1116-20.
27. Neuhaus P, Mc Master P, Calne R i sur. Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. Transplant Int 1994;7(Suppl 1):S27-31.
28. Uoshima N, Karasuno T, Yagi T i sur. Late onset cyclosporine-induced cerebral blindness with abnormal SPECT imagings in a patient under-going unrelated bone marrow transplantation. Bone Marrow Transplantant 2000;26:105-8.
29. Kast R. Blocking of cyclosporine immune suppression by neuroleptics (letter). Transplantation 1989;47:1095-6.
30. Grimm G, Ferenci P, Katzenschlager R. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988;2:1392-4.
31. Als-Nielsen B, Kjaergard LL, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001;4:CD002798.
32. Basile A, Jones E. Hepatic encephalopathy and the GABA/benzodiazepine receptor chloride ionophore complex: an update. J Gastroenterol Hepatol 1988;3:387-98.